BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer

Abstract

The addition to bevacizumab to carboplatin/paclitaxel was well tolerated and resulted in a clinically meaningful treatment benefit in Chinese patients with advanced nonsquamous NSCLC.

Management of Italian Patients With Advanced Non–Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study

“…In NSCLC, several conventional treatments combined with VEGF pathway inhibitors to consolidate an antitumor effect have come forward and been characterized a safe and effective. 99,100 A recent study elucidated that the activation of Th1 cells by immune checkpoint blockade increased vessel normalization. 101 Along with the immune checkpoint inhibitors, which hold a promising future in the treatment of advanced NSCLC and a reciprocal effect between the VEGF/VEGFR pathway and immune system, a combined 2 agents targeting angiogenesis and immune checkpoints are reasonable to combat cancer synergistically.…”

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy

“…Several agents that target vascular endothelial growth factor receptor (VEGFR) have been approved for the treatment of NSCLC. In a first‐line setting, the addition of bevacizumab to chemotherapy significantly improved the clinical outcome with overall survival (OS) of 12.3 months in a Western population and 24.3 months in a Chinese population 8, 9. However, increased toxicity was observed during bevacizumab treatment and class‐related adverse events including hypertension, proteinuria, febrile neutropenia and life‐threatening pulmonary hemorrhage, particularly in squamous NSCLC 8, 9, 10.…”

“…In a first‐line setting, the addition of bevacizumab to chemotherapy significantly improved the clinical outcome with overall survival (OS) of 12.3 months in a Western population and 24.3 months in a Chinese population 8, 9. However, increased toxicity was observed during bevacizumab treatment and class‐related adverse events including hypertension, proteinuria, febrile neutropenia and life‐threatening pulmonary hemorrhage, particularly in squamous NSCLC 8, 9, 10. The approval of ramucirumab and nintedanib has provided new options for NSCLC patients who progressed on initial treatment, with improved OS and tolerable toxicity when combined with standard second‐line chemotherapy 11, 12, 13.…”

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

“…Furthermore, administering platinum doublet chemotherapy alternating with EGFR-TKI produced longer survivals among EGFR-mutants than EGFR-TKI alone [28]. In addition, some report that EGFR-mutants may be more likely to benefit from cytotoxic chemotherapy than wild type [36,37].…”